Protection against allograft rejection with intercellular adhesion molecule-1 antisense oligodeoxynucleotides

Area of Science:

• Immunology
• Molecular Biology
• Transplantation Science

Background:

• Intercellular Adhesion Molecule-1 (ICAM-1) plays a critical role in immune responses and transplant rejection.
• Targeting ICAM-1 expression is a potential strategy to improve allograft survival.

Purpose of the Study:

• To design and evaluate an antisense phosphorothioate oligodeoxynucleotide (oligo), IP-9125, for its ability to inhibit rat ICAM-1 mRNA and protein expression.
• To assess the efficacy of IP-9125 in preventing kidney and heart allograft rejection in a rat model.

Main Methods:

• An antisense oligo (IP-9125) targeting rat ICAM-1 mRNA was synthesized.
• IP-9125 was administered intravenously via osmotic pump, alone or with cyclosporine (CsA), to allograft recipients.
• Kidney allografts were also perfused with IP-9125 prior to transplantation.
• ICAM-1 expression was assessed in vitro and in vivo; allograft survival was monitored.

Main Results:

• IP-9125 significantly inhibited ICAM-1 mRNA and protein expression in endothelial cells, while scrambled controls were ineffective.
• Intravenous administration of IP-9125 prolonged kidney and heart allograft survival in a dose-dependent manner.
• Combination therapy with IP-9125 and CsA demonstrated synergistic effects, significantly extending allograft survival.
• Pre-transplant graft perfusion with IP-9125 also effectively protected kidney allografts from rejection.

Conclusions:

• The designed antisense oligo, IP-9125, effectively inhibits ICAM-1 expression both in vitro and in vivo.
• IP-9125 demonstrates significant potential in blocking allograft rejection through various administration routes, including pretreatment, graft perfusion, and postoperative treatment.
• This approach offers a promising therapeutic strategy for enhancing the success of organ transplantation by mitigating rejection.